TABLE 6.
The base case analysis.
| Types of receiving subsequent treatment | ICER(China) | PSA (China) | ICER(US) | PSA (US) |
|---|---|---|---|---|
| Ramucirumab plus paclitaxel | 53,655.01 | 2.23% | 527,134.42 | 0 |
| Ramucirumab plus paclitaxel (TAP ≥ 5%) | 26,580.24 | 88.91% | 325,541.95 | 0.17% |
| Best supportive care | 32,172.27 | 79.24% | 493,362.97 | 0 |
| Best supportive care (TAP ≥ 5%) | 27,274.97 | 87.62% | 326,171.44 | 0.11% |
| Paclitaxel | 32,620.25 | 76.59% | 485,883.39 | 0 |
| Paclitaxel (TAP ≥ 5%) | 27,001.07 | 88.24% | 329,962.44 | 0.09% |
| Docetaxel | 32,332.25 | 77.45% | 486,267.51 | 0 |
| Docetaxel (TAP ≥ 5%) | 27,177.15 | 87.82% | 329,767.75 | 0.09% |
| Nab-paclitaxel | 33,439.12 | 71.82% | 505,964.20 | 0 |
| Nab-paclitaxel (TAP ≥ 5%) | 26,500.43 | 88.83% | 319,784.53 | 0.39% |
| Irinotecan | 33,691.57 | 70.52% | 486,121.93 | 0 |
| Irinotecan (TAP ≥ 5%) | 26,346.09 | 88.61% | 329,841.54 | 0.10% |
ICER: Incremental cost-effectiveness ratio, PSA: probabilistic sensitivity analyses.